Watson's purpose is obvious, that is, the transfer of interests, and the ugly face of capitalists is exposed. It happened on February 5th, 65438, when watson biological announced that it would destroy 32.6% of the shares held by Shanghai Zerun at a price of165438+400 million yuan, which would be worth about 3.5 billion yuan if valued. After such transfection, the shareholding ratio of Shanghai Zerun will be reduced to 28.5%, and Shanghai Zerun is no longer the controlling shareholder.

First of all, talk about valuation. The biggest complaint of many minority shareholders is equity valuation. Some institutional investors pointed out that the valuation of bivalent HPV vaccine currently on the market is as high as 78.3 billion US dollars. In contrast, the market value of Shanghai Zerun is seriously underestimated. The total stock price of watson biological to Shanghai Zerun is110.20 billion yuan, and the net assets are 603 million yuan. The enterprise that can compare with Shanghai Zerun horizontally is Wan Tai Bio, with a half-year revenue of 843 million. After Zerun was listed on the Shanghai Stock Exchange at 9: 00, its market profit value must be different from that of Wan Tai Bio, so the valuation of Watson Technology is obviously lower than the market price.

Let's talk about the key contents of watson biological's equity transfer. First, after the equity transfer, watson biological is still an important shareholder of Shanghai Zerun. Secondly, watson biological gained a lot from this equity transfer. Watson biological 201140 million yuan bought the equity of Shanghai Zerun for 263 million yuan. After seven years of operation, whether it is underestimated or not, it is successful. Finally, after the equity transfer, watson biological still has the marketing right to list bivalent human papillomavirus in five years and bivalent human papillomavirus in three years, which means that although watson biological has transferred its equity, its core profit point still exists.